We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.00 | -0.03% | 12,100.00 | 12,084.00 | 12,088.00 | 12,096.00 | 11,990.00 | 12,020.00 | 923,841 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.46 | 187.63B |
RNS Number:9063W AstraZeneca PLC 9 January 2001 GENERIC CHALLENGE TO LOSEC WITHDRAWN IN CANADA AstraZeneca today announced that the Canadian Federal Court has ordered that the proceedings against Genpharm Inc, are deemed to be withdrawn, following the earlier rejection of a regulatory application by Genpharm for generic omeprazole, thus rendering the court proceedings moot. In March 1999, Genpharm Inc, advised it was seeking regulatory approval in Canada to market generic omeprazole capsules and made allegations with respect to AstraZeneca's patents. AstraZeneca responded by filing lawsuits that disputed Genpharm's allegations. In October 2000, the Canadian regulatory authority rejected Genpharm's regulatory application for its generic omeprazole product. For several years, various companies have sought to market generic omeprazole in Canada. AstraZeneca has successfully asserted its patent rights for its Losec product and no generic product has reached the market to date. AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over USD15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products. 9 January 2001 Further enquiries to: Michael Olsson Tel +44 (0)20 7304 5087 Ed Seage Tel +44 (0)20 7304 5101 Jorgen Winroth Tel +1 609 896 4148
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
